[EN] ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS<br/>[FR] INHIBITEURS DE RÉCEPTEURS ERBB UTILISÉS COMME AGENTS ANTITUMORAUX
申请人:SUZHOU ZANRONG PHARMA LTD
公开号:WO2021179274A1
公开(公告)日:2021-09-16
Provided herein are novel compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.
本文提供了作为I型受体酪氨酸激酶抑制剂的新化合物,包括其中一种或多种化合物及其盐作为活性成分的药物组合物,以及在哺乳动物,尤其是人类中治疗高增殖性疾病(如癌症和炎症)中使用这些化合物及其盐的用途。